1. Home
  2. RVPH vs APLT Comparison

RVPH vs APLT Comparison

Compare RVPH & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • APLT
  • Stock Information
  • Founded
  • RVPH 2006
  • APLT 2016
  • Country
  • RVPH United States
  • APLT United States
  • Employees
  • RVPH N/A
  • APLT N/A
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • APLT Biotechnology: Pharmaceutical Preparations
  • Sector
  • RVPH Health Care
  • APLT Health Care
  • Exchange
  • RVPH Nasdaq
  • APLT Nasdaq
  • Market Cap
  • RVPH 88.0M
  • APLT 80.3M
  • IPO Year
  • RVPH N/A
  • APLT 2019
  • Fundamental
  • Price
  • RVPH $1.80
  • APLT $0.65
  • Analyst Decision
  • RVPH Strong Buy
  • APLT Buy
  • Analyst Count
  • RVPH 5
  • APLT 7
  • Target Price
  • RVPH $11.40
  • APLT $6.10
  • AVG Volume (30 Days)
  • RVPH 1.6M
  • APLT 3.5M
  • Earning Date
  • RVPH 11-14-2024
  • APLT 03-05-2025
  • Dividend Yield
  • RVPH N/A
  • APLT N/A
  • EPS Growth
  • RVPH N/A
  • APLT N/A
  • EPS
  • RVPH N/A
  • APLT N/A
  • Revenue
  • RVPH N/A
  • APLT N/A
  • Revenue This Year
  • RVPH N/A
  • APLT N/A
  • Revenue Next Year
  • RVPH N/A
  • APLT $2,622.90
  • P/E Ratio
  • RVPH N/A
  • APLT N/A
  • Revenue Growth
  • RVPH N/A
  • APLT N/A
  • 52 Week Low
  • RVPH $0.60
  • APLT $0.54
  • 52 Week High
  • RVPH $4.50
  • APLT $10.62
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 45.36
  • APLT 35.67
  • Support Level
  • RVPH $1.97
  • APLT $0.54
  • Resistance Level
  • RVPH $2.14
  • APLT $0.66
  • Average True Range (ATR)
  • RVPH 0.16
  • APLT 0.06
  • MACD
  • RVPH -0.02
  • APLT 0.09
  • Stochastic Oscillator
  • RVPH 29.29
  • APLT 81.26

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

About APLT Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Share on Social Networks: